Bullous Pemphigoid: Trigger and Predisposing Factors

Kasperkiewicz, 2007, The Pathophysiology of Bullous Pemphigoid, Clin. Rev. Allergy Immunol., 33, 67, 10.1007/s12016-007-0030-y

Feliciani, 2009, IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses, Br. J. Dermatol., 161, 306, 10.1111/j.1365-2133.2009.09266.x

Fania, 2012, IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses, Clin. Immunol., 143, 236, 10.1016/j.clim.2012.02.003

Fontao, 2008, Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid, Clin. Immunol., 128, 415, 10.1016/j.clim.2008.04.012

Uter, 2006, Autoreactive T and B Cells from Bullous Pemphigoid (BP) Patients Recognize Epitopes Clustered in Distinct Regions of BP180 and BP230, J. Immunol., 176, 2015, 10.4049/jimmunol.176.3.2015

Arakawa, 2011, Lesional Th17 cells and regulatory T-cells in bullous pemphigoid, Exp. Dermatol., 20, 1022, 10.1111/j.1600-0625.2011.01378.x

Goldring, C.E., Sanderson, J.P., and Naisbitt, D.J. (2007). Drugs as Haptens, Antigens, and Immunogens. Drug Hypersensitivity, Karger Publishers.

Nelson, C.A., Singer, S., Chen, T., Puleo, A.E., Lian, C.G., Wei, E.X., Giobbie-Hurder, A., Mostaghimi, A., and Leboeuf, N.R. (2020). Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes. J. Am. Acad. Dermatol.

Popadic, 2009, Bullous pemphigoid induced by penicillamine in a patient with Wilson disease, Am. J. Clin. Dermatol., 10, 36, 10.2165/0128071-200910010-00006

Cozzani, 2016, Ciprofloxacin as a Trigger for Bullous Pemphigoid, Am. J. Ther., 23, e1202, 10.1097/MJT.0000000000000283

Harada, M., Yoneda, A., Haruyama, S., Yabuki, K., Honma, Y., Hiura, M., Shibata, M., Matsuoka, H., and Uchiwa, Y. (2017). Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma. Intern. Med.

Pankakoski, 2018, Comorbidities of bullous pemphigoid in a Finnish cohort, Eur. J. Dermatol., 28, 157, 10.1684/ejd.2018.3243

Ma, 2012, Case of drug-induced bullous pemphigoid by levofloxacin, J. Dermatol., 39, 1086, 10.1111/j.1346-8138.2012.01636.x

Carlos, 2015, A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab, Melanoma Res., 25, 265, 10.1097/CMR.0000000000000155

Naidoo, 2016, Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1, Cancer Immunol. Res., 4, 383, 10.1158/2326-6066.CIR-15-0123

Parakh, 2016, Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma, Australas. J. Dermatol., 58, e109

Rofe, 2017, Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression, Clin. Exp. Dermatol., 42, 309, 10.1111/ced.13042

Siegel, 2018, Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy, J. Am. Acad. Dermatol., 79, 1081, 10.1016/j.jaad.2018.07.008

Sadik, 2019, Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid, Front. Immunol., 10, 1934, 10.3389/fimmu.2019.01934

Vassileva, 1998, Drug-induced pemphigoid: Bullous and cicatricial, Clin. Dermatol., 16, 379, 10.1016/S0738-081X(98)00008-X

Warner, 2014, Bullous pemphigoid induced by hydrochlorothiazide therapy, J. Drugs Dermatol., 13, 360

Moitra, 2015, Metronidazole-Induced Bullous Pemphigoid: A Case Report, J. Clin. Diagn. Res., 9, FD01

Bordignon, 2009, Bullous Pemphigoid during Long-Term TNF-α Blocker Therapy, Dermatology, 219, 357, 10.1159/000243805

Gaudin, O., Seta, V., Alexandre, M., Bohelay, G., Aucouturier, F., Mignot-Grootenboer, S., Ingen-Housz-Oro, S., Bernardeschi, C., Schneider, P., and Mellottee, B. (2018). Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. Front. Immunol., 9.

Pasmatzi, 2011, Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases, Diabetes Care, 34, e133, 10.2337/dc11-0804

Skandalis, 2011, Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin, J. Eur. Acad. Dermatol. Venereol., 26, 249, 10.1111/j.1468-3083.2011.04062.x

Aouidad, 2013, A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors, JAMA Dermatol., 149, 243, 10.1001/jamadermatol.2013.1073

2016, Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors—One due to Linagliptin, Dermatology, 232, 249, 10.1159/000443330

Jacobsoone, 2014, Bullous pemphigoid induced by vildagliptin: A report of three cases, Fundam. Clin. Pharmacol., 29, 112

Ivars, 2018, Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization, Int. J. Dermatol., 57, 810, 10.1111/ijd.14005

Mai, Y., Nishie, W., Sato, K., Hotta, M., Izumi, K., Ito, K., Hosokawa, K., and Shimizu, H. (2018). Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature. Front. Immunol., 9.

Fania, 2018, Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors, J. Am. Acad. Dermatol., 78, 592, 10.1016/j.jaad.2017.09.051

Soualhi, 2011, Une forme rare de toxidermie induite par la rifampicine: La pemphigoïde bulleuse, Rev. Mal. Respir., 28, 365, 10.1016/j.rmr.2010.09.031

Takama, 2018, Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading, Acta Derm. Venereol., 98, 983, 10.2340/00015555-3010

Lindgren, 2019, Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid, Acta Derm. Venereol., 99, 602, 10.2340/00015555-3166

Mai, Y., Nishie, W., Izumi, K., and Shimizu, H. (2019). Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180. Front. Immunol., 10.

Hayashi, 2019, Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A single-centre study, Br. J. Dermatol., 182, 806, 10.1111/bjd.18516

Jha, 2020, Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases, Diabetes Metab. Syndr. Clin. Res. Rev., 14, 213, 10.1016/j.dsx.2020.03.001

Guillot, 2009, Bullous Pemphigoid Occurring during Efalizumab Treatment for Psoriasis: A Paradoxical Auto-Immune Reaction?, Dermatology, 219, 89, 10.1159/000207792

Deleuran, 2009, Development of bullous pemphigoid during treatment of psoriasis with adalimumab, Clin. Exp. Dermatol., 34, e285, 10.1111/j.1365-2230.2008.03204.x

Wessman, 2017, Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis, JAAD Case Rep., 3, 339, 10.1016/j.jdcr.2017.03.008

Hoffmann, 2018, Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis, Case Rep. Dermatol., 10, 145, 10.1159/000489163

Ricci, 2014, Bullous pemphigoid occurring under anti-tumor necrosis factor-α therapy, Int. J. Color. Dis., 29, 1573, 10.1007/s00384-014-1924-9

Boussemart, 2010, Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports, Dermatology, 221, 201, 10.1159/000318008

Wilmer, 2016, Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient, JAAD Case Rep., 2, 25, 10.1016/j.jdcr.2015.12.006

Kridin, 2018, Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study, Immunol. Res., 66, 425, 10.1007/s12026-018-9005-8

Izumi, 2016, Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid, J. Investig. Dermatol., 136, 2201, 10.1016/j.jid.2016.06.622

Forssmann, 2008, Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo, J. Immunol., 181, 1120, 10.4049/jimmunol.181.2.1120

Yoshiji, 2017, Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases, J. Diabetes Investig., 9, 445, 10.1111/jdi.12695

Haber, 2016, Bullous Pemphigoid Associated With Linagliptin Treatment, JAMA Dermatol., 152, 224, 10.1001/jamadermatol.2015.2939

Sakai, 2016, Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP 180, Br. J. Dermatol., 176, 541, 10.1111/bjd.15111

Mai, 2018, Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: A report of three patients, Br. J. Dermatol., 179, 790, 10.1111/bjd.16656

Oya, 2018, Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment, Eur. J. Dermatol., 28, 250, 10.1684/ejd.2018.3230

Guliani, 2018, Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes, Postgrad. Med. J., 94, 662, 10.1136/postgradmedj-2018-136044

Maki, 2018, Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis, J. Dermatol., 45, 600, 10.1111/1346-8138.14254

Benzaquen, 2018, Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland, J. Am. Acad. Dermatol., 78, 1090, 10.1016/j.jaad.2017.12.038

Varpuluoma, 2018, Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study, J. Investig. Dermatol., 138, 1659, 10.1016/j.jid.2018.01.027

Kawaguchi, 2018, Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients, J. Diabetes Investig., 10, 392, 10.1111/jdi.12877

Kridin, 2018, Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 Inhibitors in Patients with Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients, JAMA Dermatol., 154, 1152, 10.1001/jamadermatol.2018.2352

Plaquevent, 2019, Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population, J. Investig. Dermatol., 139, 835, 10.1016/j.jid.2018.10.045

Lee, 2019, Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes, JAMA Dermatol., 155, 172, 10.1001/jamadermatol.2018.4556

Douros, 2019, Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes, Diabetes Care, 42, 1496, 10.2337/dc19-0409

Carnovale, 2019, Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: A pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®, Expert Opin. Drug Saf., 18, 1099, 10.1080/14740338.2019.1668373

Magdaleno-Tapial, J., Valenzuela-Oñate, C., Hurtado, Á.E., Ortiz-Salvador, J.M., Subiabre-Ferrer, D., Ferrer-Guillén, B., Giacaman-von der Weth, M., Martínez, M.G.L., Martínez-Domenech, Á., and Hernández-Bel, P. (2019). Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study. Actas Dermosifiliogr.

Kodera, 2019, Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors, Jpn. J. Geriatr., 56, 43, 10.3143/geriatrics.56.43

Guo, 2020, The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study, J. Diabetes Complicat., 34, 107515, 10.1016/j.jdiacomp.2019.107515

Reolid, 2019, Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database, Int. J. Dermatol., 59, 197, 10.1111/ijd.14658

Hung, 2019, Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan, J. Dermatol., 47, 245, 10.1111/1346-8138.15195

Fania, 2018, Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade, J. Eur. Acad. Dermatol. Venereol., 32, e153, 10.1111/jdv.14649

Bene, 2016, The French Association of Regional Pharmacovigilance Centres Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors: A Case/Non-Case study in the French Pharmacovigilance Database, Br. J. Dermatol., 175, 296, 10.1111/bjd.14601

Garcia, 2016, Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database, J. Clin. Pharm. Ther., 41, 368, 10.1111/jcpt.12397

Keseroglu, 2016, A Case of Bullous Pemphigoid Induced by Vildagliptin, Cutan. Ocul. Toxicol., 36, 201, 10.1080/15569527.2016.1211670

Schaffer, 2017, Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid, Dermatology, 233, 401, 10.1159/000480498

Ujiie, 2018, HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors, J. Investig. Dermatol., 138, 1201, 10.1016/j.jid.2017.11.023

Ameglio, 1997, Bullous pemphigoid and pemphigus vulgaris: Correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels, J. Biol. Regul. Homeost. Agents, 11, 148

Ballesca, 2018, Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature, Actas Dermo-Sifiliogr. (Engl. Ed.), 109, 791, 10.1016/j.adengl.2018.09.012

Stavropoulos, 2014, Drug-induced pemphigoid: A review of the literature, J. Eur. Acad. Dermatol. Venereol., 28, 1133, 10.1111/jdv.12366

Liu, 2007, Generation of Th1 and Th2 Chemokines by Human Eosinophils: Evidence for a Critical Role of TNF-α, J. Immunol., 179, 4840, 10.4049/jimmunol.179.7.4840

Kanahara, 2016, Drug-induced bullous pemphigoid, J. Gen. Intern. Med., 31, 1393, 10.1007/s11606-016-3679-1

Bernard, 2017, Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment, Am. J. Clin. Dermatol., 18, 513, 10.1007/s40257-017-0264-2

Chi, 2013, The Associations between Bullous Pemphigoid and Drug Use, JAMA Dermatol., 149, 58, 10.1001/2013.jamadermatol.376

Joly, 2011, Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control Study, J. Investig. Dermatol., 131, 637, 10.1038/jid.2010.301

Francisco, 2010, The PD-1 pathway in tolerance and autoimmunity, Immunol. Rev., 236, 219, 10.1111/j.1600-065X.2010.00923.x

Thibult, 2012, PD-1 is a novel regulator of human B-cell activation, Int. Immunol., 25, 129, 10.1093/intimm/dxs098

Xia, 2016, Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, Biochim. Biophys. Acta (BBA) Rev. Cancer, 1865, 58, 10.1016/j.bbcan.2015.09.002

Jour, 2016, Autoimmune Dermatologic Toxicities from Immune Checkpoint Blockade with anti-PD-1 Antibody Therapy: A Report on Bullous Skin Eruptions, J. Cutan. Pathol., 43, 688, 10.1111/cup.12717

Patsatsi, 2009, Medication history of a series of patients with bullous pemphigoid from northern Greece—Observations and discussion, Int. J. Dermatol., 48, 132, 10.1111/j.1365-4632.2009.03839.x

Joly, 1996, Drugs Associated With Bullous Pemphigoid, Arch. Dermatol., 132, 272, 10.1001/archderm.1996.03890270044006

Varpuluoma, 2019, Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: A case–control study, J. Am. Acad. Dermatol., 81, 250, 10.1016/j.jaad.2019.02.017

Doval, 2006, Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain, Br. J. Dermatol., 155, 820, 10.1111/j.1365-2133.2006.07411.x

Fournier, 1996, Bullous pemphigoid induced by vaccination, Br. J. Dermatol., 135, 153, 10.1046/j.1365-2133.1996.d01-963.x

Doval, 2001, Generalized Bullous Fixed Drug Eruption after Influenza Vaccination, Simulating Bullous Pemphigoid, Acta Derm. Venereol., 81, 450, 10.1080/000155501317208534

Downs, 1998, Does influenza vaccination induce bullous pemphigoid? A report of four cases, Br. J. Dermatol., 138, 363, 10.1046/j.1365-2133.1998.02097.x

Guerra, 2018, Infantile bullous pemphigoid following vaccination, Eur. J. Dermatol., 28, 708, 10.1684/ejd.2018.3383

Baykal, 2001, Childhood bullous pemphigoid developed after the first vaccination, J. Am. Acad. Dermatol., 44, 348, 10.1067/mjd.2001.103034

Schiavo, 2013, Bullous pemphigoid: Etiology, pathogenesis, and inducing factors: Facts and controversies, Clin. Dermatol., 31, 391, 10.1016/j.clindermatol.2013.01.006

Drago, 2005, Human herpesviruses in bullous pemphigoid lesions, Br. J. Dermatol., 152, 375, 10.1111/j.1365-2133.2005.06331.x

Sagi, 2011, Autoimmune bullous diseases. The spectrum of infectious agent antibodies and review of the literature, Autoimmun. Rev., 10, 527, 10.1016/j.autrev.2011.04.003

Barrick, 2016, Herpes zoster in patients with bullous pemphigoid: A population-based case-control and cohort study, Br. J. Dermatol., 174, 1112, 10.1111/bjd.14321

Blazsek, 2008, Searching for foreign antigens as possible triggering factors of autoimmunity: Torque Teno virus DNA prevalence is elevated in sera of patients with bullous pemphigoid, Exp. Dermatol., 17, 446, 10.1111/j.1600-0625.2007.00663.x

Min, 2018, Autoimmune blistering disorders in the setting of human immunodeficiency virus infection, Int. J. Women’s Dermatol., 4, 159, 10.1016/j.ijwd.2018.02.002

De, 2008, Bullous eruption in a patient infected with the human immunodeficiency virus, Skinmed, 7, 98, 10.1111/j.1751-7125.2008.07160.x

Bull, 1994, Autoimmune blistering diseases associated with HIV infection, Clin. Exp. Dermatol., 19, 47, 10.1111/j.1365-2230.1994.tb01114.x

Levy, 1986, Ritodrine-responsive bullous pemphigoid in a patient with AIDS-related complex, Br. J. Dermatol., 114, 635, 10.1111/j.1365-2133.1986.tb04073.x

Jang, 2018, Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report, Medicine, 97, e0377, 10.1097/MD.0000000000010377

2016, Localized bullous pemphigoid triggered by erysipelas, Hautarzt, 67, 829

Partscht, 2001, Bullous scabies and scabies-triggered bullous pemphigoid, Hautarzt, 52, 56

Mul, 2007, Radiation-induced bullous pemphigoid: A systematic review of an unusual radiation side effect, Radiother. Oncol., 82, 5, 10.1016/j.radonc.2006.11.014

Chiorean, 2015, Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work, J. Dermatol., 43, 134

Nguyen, 2014, Relationship between Radiation Therapy and Bullous Pemphigoid, J. Dermatol., 229, 88, 10.1159/000362208

Hung, 2019, Risk of radiotherapy-associated autoimmune bullous disease among Taiwanese patients with breast cancer: A case–control study, Arch. Dermatol. Res., 312, 69, 10.1007/s00403-019-01985-y

Tanita, 2018, Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab, Case Rep. Oncol., 11, 114, 10.1159/000487127

Grimaux, X., Delva, R., Jadaud, E., and Croue, A. (2018). Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas. J. Dermatol., 60.

Hirotsu, 2017, Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy, JAAD Case Rep., 3, 404, 10.1016/j.jdcr.2017.06.004

Morita, 2015, Case of burn-associated bullous pemphigoid caused by anti-BP230 immunoglobulin G autoantibodies, J. Dermatol., 42, 657, 10.1111/1346-8138.12848

Vassileva, 1995, Burn-Induced Bullous Pemphigoid, Int. J. Dermatol., 34, 516

Bachmeyer, 2010, Bullous Pemphigoid After Boiling Water Burn, South. Med. J., 103, 1175, 10.1097/SMJ.0b013e3181efb58c

Chen, 1998, A bullous pemphigoid-like skin eruption after a chemical burn, J. Am. Acad. Dermatol., 38, 337, 10.1016/S0190-9622(98)70578-X

Massa, 1996, Localized bullous pemphigoid occurring in a surgical wound, Dermatol. Nurs., 8, 101

Schiavo, A.L., Caccavale, S., Alfano, R., Gambardella, A., and Cozzi, R. (2013). Bullous pemphigoid initially localized around the surgical wound of an arthroprothesis for coxarthrosis. Int. J. Dermatol., 53.

McGrath, 1991, Split skin grafting and bullous pemphigoid, Clin. Exp. Dermatol., 16, 72, 10.1111/j.1365-2230.1991.tb00306.x

Ghura, 2001, Development of a bullous pemphigoid after split-skin grafting, Br. J. Plast. Surg., 54, 447, 10.1054/bjps.2001.3601

Levin, 1994, Blistering on a squamous cell carcinoma graft site in a patient with bullous pemphigoid, Cutis, 54, 40

Marzano, 2010, Peristomal bullous pemphigoid, J. Dermatol., 37, 840, 10.1111/j.1346-8138.2010.00851.x

Batalla, 2011, Localized bullous pemphigoid at urostomy site, Indian J. Dermatol. Venereol. Leprol., 77, 625, 10.4103/0378-6323.84067

Valiallah, 2015, An asymptomatic bullous eruption arising from an old scar, Br. J. Dermatol., 173, 14

2016, PUVA-induced Bullous Pemphigoid in Psoriasis, Acta Dermatovenerol. Croat., 24, 214

Brun, 1982, Bullous pemphigoid induced by PUVA therapy for psoriasis. Report of 2 cases and review of the 6 cases in the literature, Ann. Dermatol. Venereol., 109, 461

Preesman, 1990, UV-B-induced bullous pemphigoid restricted to mycosis fungoides plaques, Clin. Exp. Dermatol., 15, 363, 10.1111/j.1365-2230.1990.tb02115.x

Korekawa, 2015, Mycosis fungoides bullosa associated with bullous pemphigoid, Int. J. Dermatol., 54, e366, 10.1111/ijd.12821

Ho, 2019, Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide population-based cohort study in Taiwan, J. Dermatol., 46, 604, 10.1111/1346-8138.14902

Barnadas, 2006, Bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: Study by ELISA test, Int. J. Dermatol., 45, 1089, 10.1111/j.1365-4632.2004.02517.x

Wilczek, 2006, Concomitant psoriasis and bullous pemphigoid: Coincidence or pathogenic relationship?, Int. J. Dermatol., 45, 1353, 10.1111/j.1365-4632.2006.02861.x

Danno, 1984, Alterations in Lectin Binding to the Epidermis Following Treatment with 8-Methoxypsoralen Plus Long-Wave Ultraviolet Radiation, J. Investig. Dermatol., 82, 176, 10.1111/1523-1747.ep12259746

George, 1995, Bullous pemphigoid possibly induced by psoralen plus ultraviolet a therapy, Photodermatol. Photoimmunol. Photomed., 11, 185, 10.1111/j.1600-0781.1995.tb00166.x

Caccavale, 2017, Bullous pemphigoid induced by photodynamic therapy: When light is guilty, Int. J. Dermatol., 56, e187, 10.1111/ijd.13613

Rakvit, 2011, Localized bullous pemphigoid induced by photodynamic therapy, Photodermatol. Photoimmunol. Photomed., 27, 251, 10.1111/j.1600-0781.2011.00609.x

Isohashi, 2011, A Case of Bullous Pemphigoid Exacerbated by Irradiation after Breast Conservative Radiotherapy, Jpn. J. Clin. Oncol., 41, 811, 10.1093/jjco/hyr049

Nieder, 2015, Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous Pemphigoid, Case Rep. Oncol. Med., 2015, 1

Sears, 2012, Bullous pemphigoid induced by radiotherapy recurring on rechallenge, Clin. Exp. Dermatol., 37, 916, 10.1111/j.1365-2230.2012.04402.x

Mitsuhashi, 1994, Bullous Pemphigoid Sera Induce Bullous-Pemphigoid-Like Lesions in Neonatal Mice Pretreated with a Limited Dose of Ultraviolet B Irradiation, Dermatology, 189, 76, 10.1159/000246936

Hall, 1993, Rabbits Immunized with a Peptide Encoded for by the 230-kD bullous Pemphigoid Antigen cDNA Develop an Enhanced Inflammatory Response to UVB Irradiation: A Potential Animal Model for Bullous Pemphigoid, J. Investig. Dermatol., 101, 9, 10.1111/1523-1747.ep12358276

Chen, 2009, Bullous Pemphigoid in a Renal Transplant Recipient, Am. J. Clin. Dermatol., 10, 197, 10.2165/00128071-200910030-00007

Kerkar, 2006, Bullous pemphigoid after liver transplantation for liver failure, Liver Transplant., 12, 1705, 10.1002/lt.20930

Atakan, 1993, Dyshidrosiform pemphigoid induced by nickel in the diet, Contact Dermat., 29, 159, 10.1111/j.1600-0536.1993.tb03520.x

Pomponi, 2013, Detection of IgG and IgE reactivity to BP180 using the ISAC®microarray system, Br. J. Dermatol., 168, 1205, 10.1111/bjd.12161

Borradori, 1998, Identification and characterization of autoreactive T-cell responses to bullous pemphigoid antigen 2 in patients and healthy controls, J. Clin. Investig., 102, 2082, 10.1172/JCI3335

Okazaki, 2000, Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid, J. Dermatol., 27, 149, 10.1111/j.1346-8138.2000.tb02141.x

Gao, 2002, HLA-DR and DQ polymorphisms in bullous pemphigoid from northern China, Clin. Exp. Dermatol., 27, 319, 10.1046/j.1365-2230.2002.01037.x

Esmaili, 2013, Association between HLA-DQB1*03:01 and Bullous pemphigoid in Iranian patients, Iran. J. Immunol., 10, 1

Sun, 2018, The HLA-DQB1*03:01 Is Associated with Bullous Pemphigoid in the Han Chinese Population, J. Investig. Dermatol., 138, 1874, 10.1016/j.jid.2018.02.021

Banfield, 1998, The association of HLA-DQ7 with bullous pemphigoid is restricted to men, Br. J. Dermatol., 138, 1085, 10.1046/j.1365-2133.1998.02350.x

Chan, 1997, Significantly Increased Occurrence of HLA-DQB1∗0301 Allele in Patients with Ocular Cicatricial Pemphigoid, J. Investig. Dermatol., 108, 129, 10.1111/1523-1747.ep12332352

Delgado, 1996, A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid, Proc. Natl. Acad. Sci. USA, 93, 8569, 10.1073/pnas.93.16.8569

Setterfield, 2001, Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production, Br. J. Dermatol., 145, 406, 10.1046/j.1365-2133.2001.04380.x

Ahmed, 1977, HLA in Bullous Pemphigoid, Arch. Dermatol., 113, 1121, 10.1001/archderm.1977.01640080123024

Ahmed, 1984, DR Antigens in Bullous Pemphigoid, Arch. Dermatol., 120, 795, 10.1001/archderm.1984.01650420105026

Schaller, 1991, HLA in Bullous Pemphigoid: The Probable Role of HLA-B7 as a Marker for Poor Responders to Immunosuppressive Therapy, Int. J. Dermatol., 30, 36, 10.1111/j.1365-4362.1991.tb05876.x

Venning, 1989, HLA type in bullous pemphigoid, cicatricial pemphigoid and linear IgA disease, Clin. Exp. Dermatol., 14, 283, 10.1111/j.1365-2230.1989.tb01980.x

Brochado, 2016, Differential HLA class I and class II associations in pemphigus foliaceus and pemphigus vulgaris patients from a prevalent Southeastern Brazilian region, J. Autoimmun., 72, 19, 10.1016/j.jaut.2016.04.007

Fang, 2017, Association of HLA class I and class II alleles with bullous pemphigoid in Chinese Hans, J. Dermatol. Sci., 89, 258, 10.1016/j.jdermsci.2017.11.014

Hirose, 2015, Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population, Exp. Dermatol., 24, 715, 10.1111/exd.12732

Jedlickova, 2010, Bullous pemphigoid and internal diseases—A case-control study, Eur. J. Dermatol., 20, 96, 10.1684/ejd.2010.0805

Taghipour, 2010, The Association of Bullous Pemphigoid with Cerebrovascular Disease and Dementia, Arch. Dermatol., 146, 1251, 10.1001/archdermatol.2010.322

Langan, 2011, The Relationship between Neurological Disease and Bullous Pemphigoid: A Population-Based Case–Control Study, J. Investig. Dermatol., 131, 631, 10.1038/jid.2010.357

Jeon, H.W., Yun, S.J., Lee, S.-C., Won, Y.H., and Lee, J.-B. (2018). Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea. Ann. Dermatol., 30.

Chen, 2011, Comorbidity profiles among patients with bullous pemphigoid: A nationwide population-based study, Br. J. Dermatol., 165, 593, 10.1111/j.1365-2133.2011.10386.x

Oh, 2015, A review of case-control studies on the risk factors for the development of autoimmune blistering diseases, J. Eur. Acad. Dermatol. Venereol., 30, 595, 10.1111/jdv.13386

Kibsgaard, 2017, Increased frequency of multiple sclerosis among patients with bullous pemphigoid: A population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid, Br. J. Dermatol., 176, 1486, 10.1111/bjd.15405

Lai, 2016, Bullous pemphigoid and its association with neurological diseases: A systematic review and meta-analysis, J. Eur. Acad. Dermatol. Venereol., 30, 2007, 10.1111/jdv.13660

Laffitte, 2005, Bullous pemphigoid antigen 1 isoforms: Potential new target autoantigens in multiple sclerosis?, Br. J. Dermatol., 152, 537, 10.1111/j.1365-2133.2004.06338.x

Foureur, 2006, Correlation between the presence of type-2 anti-pemphigoid antibodies and dementia in elderly subjects with no clinical signs of pemphigoid, Ann. Dermatol. Venereol., 133, 439, 10.1016/S0151-9638(06)70935-8

Kokkonen, 2017, Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer’s Disease, J. Investig. Dermatol., 137, 71, 10.1016/j.jid.2016.09.010

Taghipour, 2013, Immunopathological characteristics of patients with bullous pemphigoid and neurological disease, J. Eur. Acad. Dermatol. Venereol., 28, 569, 10.1111/jdv.12136

Kaczmarek, 2017, Analysis of the autoimmune response against BP180 and BP230 in ethnic Poles with neurodegenerative disorders and bullous pemphigoid, Central Eur. J. Immunol., 42, 85

Alafuzoff, 2006, Collagen XVII is expressed in human CNS neurons, Matrix Biol., 25, 185, 10.1016/j.matbio.2005.11.004

Teixeira, 2014, Bullous pemphigoid and comorbidities: A case-control study in Portuguese patients*, An. Bras. Dermatol., 89, 274, 10.1590/abd1806-4841.20142516

Brick, 2014, A population-based study of the association between bullous pemphigoid and neurologic disorders, J. Am. Acad. Dermatol., 71, 1191, 10.1016/j.jaad.2014.07.052

Cai, 2014, Mortality of bullous pemphigoid in Singapore: Risk factors and causes of death in 359 patients seen at the National Skin Centre, Br. J. Dermatol., 170, 1319, 10.1111/bjd.12806

Lillicrap, 1963, Rheumatoid Arthritis and Pemphigoid, Proc. R. Soc. Med., 56, 921

Callen, 1980, Internal disorders associated with bullous disease of the skin, J. Am. Acad. Dermatol., 3, 107, 10.1016/S0190-9622(80)80247-7

Taylor, 1993, Bullous pemphigoid and autoimmunity, J. Am. Acad. Dermatol., 29, 181, 10.1016/0190-9622(93)70164-O

Callen, 1978, Bullous pemphigoid and other disorders associated with autoimmune phenomena, Arch. Dermatol., 114, 245, 10.1001/archderm.1978.01640140063015

Giannini, 1981, Bullous pemphigoid and rheumatoid arthritis, J. Am. Acad. Dermatol., 4, 695, 10.1016/S0190-9622(81)80202-2

Savin, 1979, The events leading to the death of patients with pemphigus and pemphigoid, Br. J. Dermatol., 101, 521, 10.1111/j.1365-2133.1979.tb11881.x

Dahl, 1987, Bullous pemphigoid: Associated diseases, Clin. Dermatol., 5, 64, 10.1016/0738-081X(87)90051-4

Person, 1977, Benign: Bullous and cicatricial pemphigoid, clinical, histopathologic and immunopathologic correlations, Plast. Reconstr. Surg., 60, 486, 10.1097/00006534-197709000-00095

Dainichi, T., and Kabashima, K. (2018). Interaction of Psoriasis and Bullous Diseases. Front. Med., 5.

Tsai, 2011, Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan, J. Dermatol. Sci., 63, 40, 10.1016/j.jdermsci.2011.03.002

Kridin, 2017, Association between pemphigus and psoriasis: A population-based large-scale study, J. Am. Acad. Dermatol., 77, 1174, 10.1016/j.jaad.2017.07.007

Ohata, 2015, Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases, J. Am. Acad. Dermatol., 73, 50, 10.1016/j.jaad.2015.03.016

Balestri, 2015, Malignancies in bullous pemphigoid: A controversial association, J. Dermatol., 43, 125, 10.1111/1346-8138.13079

Atzmony, 2017, Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis, J. Am. Acad. Dermatol., 77, 691, 10.1016/j.jaad.2017.05.006

Lucariello, 2018, Association between bullous pemphigoid and malignancy: A meta-analysis, Australas. J. Dermatol., 59, 253, 10.1111/ajd.12764

Schulze, 2015, Malignancies in Pemphigus and Pemphigoid Diseases, J. Investig. Dermatol., 135, 1445, 10.1038/jid.2014.547

Ong, 2013, Associations between bullous pemphigoid and primary malignant cancers: An English national record linkage study, 1999–2011, Arch. Dermatol. Res., 306, 75, 10.1007/s00403-013-1399-5

Bech, R., Kibsgaard, L., and Vestergaard, C. (2018). Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature. Front. Med., 5.

Yan, 2019, Coagulation Disorders in Bullous Pemphigoid and Its Mechanism, Acta Acad. Med. Sin., 41, 685

Roujeau, 1998, High risk of death in elderly patients with extensive bullous pemphigoid, Arch. Dermatol., 134, 465, 10.1001/archderm.134.4.465

Echigo, 2007, Antiphospholipid antibodies in patients with autoimmune blistering disease, J. Am. Acad. Dermatol., 57, 397, 10.1016/j.jaad.2006.07.004

Langan, 2009, A population-based study of acute medical conditions associated with bullous pemphigoid, Br. J. Dermatol., 161, 1149, 10.1111/j.1365-2133.2009.09350.x

Yang, 2011, Increased Risk of Stroke in Patients With Bullous Pemphigoid, Stroke, 42, 319, 10.1161/STROKEAHA.110.596361

Marzano, 2012, Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease, Clin. Exp. Immunol., 171, 76, 10.1111/j.1365-2249.2012.04674.x

Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemost., 4, 295, 10.1111/j.1538-7836.2006.01753.x

Maia, 2017, Stroke in systemic lupus erythematosus and antiphospholipid syndrome: Risk factors, clinical manifestations, neuroimaging, and treatment, Lupus, 26, 529, 10.1177/0961203316688784

Gin, H., Vergnot, V., Diakou, V., Perret, A.-M., Poix, J., Cassagne, C., and Maneta-Peyret, L. (2002). Anti-Phospholipid Antibodies in Diabetes Mellitus. Clin. Chem. Lab. Med., 40.

Abaci, 2010, Prevalence of anticardiolipin antibodies in type 1 diabetes and autoimmune thyroiditis, Pol. Arch. Med. Wewn., 120, 71, 10.20452/pamw.889

Kaji, 2002, Antiphospholipid Syndrome and Multiple Ischemic Strokes in a Patient with Myasthenia Gravis, Kurume Med. J., 49, 211, 10.2739/kurumemedj.49.211

Versini, M. (2017). Thyroid Autoimmunity and Antiphospholipid Syndrome: Not Such a Trivial Association. Front. Endocrinol., 8.

Koutroubakis, 1998, Anti-cardiolipin and Anti-β2-glycoprotein I Antibodies in Patients with Inflammatory Bowel Disease, Dig. Dis. Sci., 43, 2507, 10.1023/A:1026602803622

Mouelhi, 2009, Thromboses au cours des maladies inflammatoires chroniques de l’intestin: Mecanismes et facteurs de risqué, Tunis. Med., 87, 307

Roubey, 1996, Immunology of the antiphospholipid antibody syndrome, Arthritis Rheum., 39, 1444, 10.1002/art.1780390903

Riboldi, 2003, Endothelium as a target for antiphospholipid antibodies, Immunobiology, 207, 29, 10.1078/0171-2985-00211

Bucciarelli, 2016, Increased risk of venous thromboembolism in patients with bullous pemphigoid, Thromb. Haemost., 115, 193, 10.1160/TH15-04-0309

Joly, 2005, Prediction of Survival for Patients With Bullous Pemphigoid, Arch. Dermatol., 141, 691, 10.1001/archderm.141.6.691

Ungprasert, 2017, Risk of venous thromboembolism in patients with bullous pemphigoid: A systematic review and meta-analysis, Indian J. Dermatol. Venereol. Leprol., 84, 22, 10.4103/ijdvl.IJDVL_827_16

Cugno, M., Borghi, A., Garcovich, S., and Marzano, A.V. (2019). Coagulation and Skin Autoimmunity. Front. Immunol., 10.

Giusti, 2017, Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome, Sci. Rep., 7, 4833, 10.1038/s41598-017-04687-5

Tedeschi, 2014, Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid, J. Eur. Acad. Dermatol. Venereol., 29, 813, 10.1111/jdv.12464

Wakugawa, 2000, Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: Correlation with tissue eosinophilia, Br. J. Dermatol., 143, 112, 10.1046/j.1365-2133.2000.03599.x

Engineer, 2001, Bullous pemphigoid: Interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation, Cytokine, 13, 32, 10.1006/cyto.2000.0791

Frezzolini, 2004, Interleukin-16 expression and release in bullous pemphigoid, Clin. Exp. Immunol., 137, 595, 10.1111/j.1365-2249.2004.02570.x

Amber, K.T., Valdebran, M., Kridin, K., and Grando, S.A. (2018). The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease. Front. Med., 5.

Shimanovich, 2004, Granulocyte-derived elastase and gelatinase B are required for dermal–epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid, J. Pathol., 204, 519, 10.1002/path.1674

Inoue, 1994, 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen, J. Clin. Investig., 93, 2022, 10.1172/JCI117196

Marzano, 2009, Activation of blood coagulation in bullous pemphigoid: Role of eosinophils, and local and systemic implications, Br. J. Dermatol., 160, 266, 10.1111/j.1365-2133.2008.08880.x

Marzano, 2011, Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases, Clin. Exp. Immunol., 165, 44, 10.1111/j.1365-2249.2011.04391.x

DeMichele, 1990, Thrombin’s enzymatic activity increases permeability of endothelial cell monolayers, J. Appl. Physiol., 69, 1599, 10.1152/jappl.1990.69.5.1599

Marzano, 2009, Coagulation activation in autoimmune bullous diseases, Clin. Exp. Immunol., 158, 31, 10.1111/j.1365-2249.2009.03989.x

Cugno, M., Tedeschi, A., Borghi, A., Bucciarelli, P., Asero, R., Venegoni, L., Griffini, S., Grovetti, E., Berti, E., and Marzano, A.V. (2015). Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. PLoS ONE, 10.

Watad, 2017, Autoimmunity in the Elderly: Insights from Basic Science and Clinics—A Mini-Review, Gerontology, 63, 515, 10.1159/000478012

Mehr, 2011, Reversing B cell aging, Aging, 3, 438, 10.18632/aging.100313

Szabo, 2003, Impaired rearrangement of IgH V to DJ segments in bone marrow Pro-B cells from old mice, Cell. Immunol., 222, 78, 10.1016/S0008-8749(03)00084-4

Duggal, 2013, An age-related numerical and functional deficit in CD19+CD24hiCD38hi B cells is associated with an increase in systemic autoimmunity, Aging Cell, 12, 873, 10.1111/acel.12114

Weiskopf, 2009, The aging of the immune system, Transpl. Int., 22, 1041, 10.1111/j.1432-2277.2009.00927.x

Naradikian, 2015, Age-associated B cells: Key mediators of both protective and autoreactive humoral responses, Immunol. Rev., 269, 118, 10.1111/imr.12380

Vadasz, Z., Haj, T., Kessel, A., and Toubi, E. (2013). Age-related autoimmunity. BMC Med., 11.

Akha, 2018, Aging and the immune system: An overview, J. Immunol. Methods, 463, 21, 10.1016/j.jim.2018.08.005

Karnell, 2017, Role of CD11c+ T-bet+ B cells in human health and disease, Cell. Immunol., 321, 40, 10.1016/j.cellimm.2017.05.008

Rubtsov, 2011, Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity, Blood, 118, 1305, 10.1182/blood-2011-01-331462

Lindstrom, 2010, Rheumatoid arthritis: A role for immunosenescence?, J. Am. Geriatr. Soc., 58, 1565, 10.1111/j.1532-5415.2010.02965.x

Pereira, B.I., and Akbar, A.N. (2016). Convergence of Innate and Adaptive Immunity during Human Aging. Front. Immunol., 7.

Ponnappan, 2011, Aging and Immune Function: Molecular Mechanisms to Interventions, Antioxid. Redox Signal., 14, 1551, 10.1089/ars.2010.3228

Mellanby, 2009, Role of regulatory T-cells in autoimmunity, Clin. Sci., 116, 639, 10.1042/CS20080200

Linehan, 2015, Ageing and the immune system: Focus on macrophages, Eur. J. Microbiol. Immunol., 5, 14, 10.1556/EuJMI-D-14-00035

Fortin, 2008, Aging and Neutrophils: There Is Still Much to Do, Rejuvenation Res., 11, 873, 10.1089/rej.2008.0750

Ray, 2009, The Role of Epigenetics in Aging and Autoimmunity, Clin. Rev. Allergy Immunol., 39, 42